LA JOLLA, California, March 5, 2021 / PRNewswire / – Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative drugs targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and CEO of Regulus, will make a presentation at the HC Wainwright Global Life Sciences Conference which will be held virtually on March 9 to 10, 2021.
A webcast of the on-demand presentation will be available from Tuesday March 9, 2021 through the investor relations section of the company’s website at www.regulusrx.com. A replay of the webcast will be archived for 30 days after the presentation date.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative drugs targeting microRNAs. Regulus has leveraged its expertise in the discovery and development of oligonucleotide drugs to develop a pipeline complemented by a rich heritage of intellectual property in the field of microRNAs. Regulus is headquartered in La Jolla, CALIFORNIA.
Statements in this press release regarding matters which are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Since such statements are subject to risks and uncertainties , actual results may differ materially from those expressed or implied by these forward-looking statements. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “objective”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Regulus’ current expectations and involve assumptions which may never materialize or prove to be incorrect. Actual results and timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, which include, but are not limited to, risks associated with the process of drug discovery, development and commercialization. safe and effective for use as human therapeutics and in the effort to build a business around these drugs, and FDA reviews. Additionally, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the magnitude of the impact on Regulus’ ability to meet its preclinical and clinical development goals and the value and market of its common stock, is dependent on future developments which are very uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, distancing requirements social and business closure in the United States and other countries; and the effectiveness of global measures to contain and treat the disease. These and other risks are described in more detail in documents filed by Regulus with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus assumes no obligation to update these statements to reflect events that have occurred or circumstances that exist after the date on which they were made.
SOURCE Regulus Therapeutics Inc.